Free press releases distribution network?

Agency / Source: IMARC Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



DPP-IV Inhibitors to Account for 17% of the Indian Oral Antidiabetics Market by 2015 Finds IMARC Group - Driven by a strong safety-efficacy profile, the market for DPP-IV inhibitors in India is expected to reach more than US$ 163 Million in the next five years. This would represent around 17% of the total oral antidiabetics market by 2015
DPP-IV Inhibitors to Account for 17% of the Indian Oral Antidiabetics Market by 2015 Finds IMARC Group

 

PRZOOM - /newswire/ - Delhi, Noida, India, 2011/07/02 - Driven by a strong safety-efficacy profile, the market for DPP-IV inhibitors in India is expected to reach more than US$ 163 Million in the next five years. This would represent around 17% of the total oral antidiabetics market by 2015.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

According to IMARC’s new research report “India Diabetes Market Report & Outlook for 2010-2015”, DPP-IV Inhibitors are expected to account for 17% of the total oral antidiabetics market by 2015. According to the research, there are currently three players operating in this market. MSD was the first to enter the market with its two drugs Januvia (Sitagliptin) and Janumet (Sitagliptin+Metformin), and represents the current market leader. The other two Players are Novartis and local manufacturer USV. Both players have tied up to market Galvus (Vidagliptin) and Eucreas (Vidagliptin+Metformin) in the Indian market.

The research thoroughly investigates the factors which will drive the growth of DPP-IV inhibitors and other oral antidiabetic drugs in India. Analysts from IMARC believe that despite the fact that DPP-IV inhibitors are more expensive than conventional oral antidiabetic drugs such as Biguanides and Sulphonylureas, there is still a significant patient population that can afford high priced innovative drugs in India. According to IMARC, the high safety-efficacy profile associated with DPP-IV Inhibitors, coupled with their rich pipeline will be a key factor in driving the growth of this market in the next five years.

Findings from the research suggest that apart from the four products already available, three new DPP-IV Inhibitors will be launched in India in the next five years. IMARC expects the DPP-IV Inhibitor market to reach sales worth more than US$ 163 Million by 2015.


“Indian Diabetes Market Report and Outlook for 2010-2015” gives a deep insight into the Indian diabetes market. The research study serves as an analytical as well as a statistical tool to understand the epidemiology, trends, market structure and segmentation, competitive landscape, drivers, restraints and the outlook of the diabetes market in India. The report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are looking to foray into the Indian diabetes market in some form or the other.

Table of Contents

1. Executive Summary
2. Diabetes Disease Overview
2.1 What Is Diabetes?
2.2 Diabetes Diagnosis And Treatment
2.2.1 Diagnosis
2.2.2 Treatment
2.3 Diabetes Complications

3. Why Is The Diabetes Market So Lucrative In India
3.1 India Has The Largest Diabetic Population In The World.
3.2 India Represents One Of The Fastest Growing Markets Globally
3.3 Improving Diagnosis And Treatment Rates
3.4 Large Untapped Market
3.5 Bright Outlook For Innovative Drugs

4. The Indian Diabetes Epidemiology
4.1 Total Prevalence
4.1.1 Type1 & Type2 Prevalence
4.1.2 Urban And Rural Prevalence
4.1.3 Prevalence Of Diabetes By Sex
4.1.4 Prevalence Of Diabetes By Age Group
4.1.5 Prevalence Of Diabetes In Various Regions In India
4.2 Diagnosis And Treatment Rates In India

5. The Indian Diabetes Market
5.1 Market Trend (2005-2009)
5.2 Market Segmentation (2005-2009)
5.3 Market Forecasts (2010-2015)

6. The Indian Non-insulin Anti-diabetics Market
6.1 Market Trend (2005-2009)
6.2 Competitive Landscape (2005-2009)
6.3 Market Forecasts (2010-2015)
6.4 Market Segmentation (2005-2015)
6.4.1 Glitazones
6.4.1.1 Market Trend (2005-2009)
6.4.1.2 Competitive Landscape
6.4.1.2.1 Share Of Key Players
6.4.1.2.2 Portfolio Of Key Players
6.4.1.3 Market Forecasts (2010-2015)
6.4.2 Biguanides
6.4.2.1 Market Trend (2005-2009)
6.4.2.2 Competitive Landscape
6.4.2.2.1 Share Of Key Players
6.4.2.2.2 Portfolio Of Key Players
6.4.2.3 Market Forecasts (2010-2015)
6.4.3 Sulphonylureas
6.4.3.1 Market Trend (2005-2009)
6.4.3.2 Competitive Landscape
6.4.3.2.1 Share Of Key Players
6.4.3.2.2 Portfolio Of Key Players
6.4.3.3 Market Forecasts (2010-2015)
6.4.4 Alpha-glycosidase Inhibitors
6.4.4.1 Market Trend (2005-2009)
6.4.4.2 Competitive Landscape
6.4.4.2.1 Share Of Key Players
6.4.4.2.2 Portfolio Of Key Players
6.4.4.3 Market Forecasts (2010-2015)
6.4.5 Dpp-iv Inhibitors
6.4.5.1 Market Trend (2008-2009)
6.4.5.2 Competitive Landscape
6.4.5.2.1 Share Of Key Players
6.4.5.2.2 Portfolio Of Key Players
6.4.5.3 Market Forecasts (2010-2015)
6.4.6 Glinides
6.4.6.1 Market Trend (2005-2009)
6.4.6.2 Competitive Landscape
6.4.6.2.1 Share Of Key Players
6.4.6.2.2 Portfolio Of Key Players
6.4.6.3 Market Forecasts (2010-2015)
6.4.7 Glp-1 Agonists
6.4.7.1 Market Trend (2008-2009)
6.4.7.2 Competitive Landscape
6.4.7.2.1 Share Of Key Players
6.4.7.2.2 Portfolio Of Key Players
6.4.7.3 Market Forecasts (2010-2015)
6.4.8 All Other Classes
6.4.8.1 Market Trend (2005-2009)
6.4.8.2 Competitive Landscape
6.4.8.2.1 Share Of Key Players
6.4.8.2.2 Portfolio Of Key Players
6.4.8.3 Market Forecasts (2010-2015)

7. The Indian Insulin Market
7.1 Market Trend (2005-2009)
7.2 Market Segmentation By Molecule (2005-2009)
7.3 Market Segmentation By Mode Of Action
7.4 Competitive Landscape
7.4.1 Share Of Key Players
7.4.2 Portfolio Of Key Players
7.5 Market Forecasts (2010-2015)

8. Road Blocks
8.1 Low Average Per Patient Spending On Diabetes Drugs
8.2 Preference For Inexpensive And Older Drug Classes
8.3 Highly Fragmented And ‘genericized’ Market
8.4 Low Rates Of Drug Treated Population In Rural Areas.

To buy the complete report or to get a free sample:

Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America) or email sales[.]imarcgroup.com or visit imarcgroup.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


DPP-IV Inhibitors to Account for 17% of the Indian Oral Antidiabetics Market by 2015 Finds IMARC Group

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From IMARC Group / Company Profile


Read Medical Services/Equipment Most Recent Related Press Releases:

Thales Launches the Pixium Portable 3543 DR Wifi Enabled Flat Panel Detector
GE Healthcare Showcases Industry-first Technologies and Digital Solutions, Focused on Improving Outcomes, At RSNA 2016
Agfa and LCsys Team Up to Launch ABSOLUT-ID, Their Turnkey Integrated Solution for the Production of High Security ID Cards
ZOLL Technology for Improving CPR Quality to be Showcased at American Heart Association Annual Conference
AccuVein to Exhibit Leading Vein Visualization Technology at American Society for Dermatologic Surgery Annual Meeting
US Biomedical Textiles Transform Implant Device Technology by Aligning to Changes in Patient Preference Finds Frost & Sullivan
Frost & Sullivan Commends Influence Health for Constantly Evolving its Patient Engagement Products to Accelerate Market Transformation
Frost & Sullivan Awards Carestream Top Honors for OnSight 3D Extremity System
Sparta Systems Launches the Next-Generation Cloud Solution Stratas QMS
Koning Wins Accolades from Frost & Sullivan for the Impressive Innovation Behind its Groundbreaking KBCT Breast Imaging Device

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Triggr & Bloom

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today